Dexketoprofen

Dexketoprofen

SCHEMBL66987

C[C@H](C(=O)O)c1cccc(C(=O)c2ccccc2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PTGS1PTGS2

The experimentally established mechanism targets of Dexketoprofen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 known ✓ P23219 6/20 1.00
PTGS2 known ✓ P35354 6/20 1.00
MAPT P10636 5/20 1.00
SMN1; SMN2 Q16637 3/20 1.00
ALDH1A1 P00352 3/20 1.00
LMNA P02545 3/20 1.00
CXCR1 P25024 2/20 1.00
CXCR2 P25025 2/20 1.00
CYP3A4 P08684 2/20 1.00
RECQL P46063 1/20 1.00
KDM4E B2RXH2 1/20 1.00
HPGD P15428 1/20 1.00
MAPK1 P28482 1/20 1.00
PMP22 Q01453 1/20 1.00
SLC22A6 Q4U2R8 1/20 1.00
HSD17B10 Q99714 1/20 1.00
CXCL8 P10145 1/20 1.00
THPO P40225 1/20 1.00
HIF1A Q16665 1/20 1.00
HTT P42858 3/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ketoprofen SCHEMBL2896 1.00 PTGS1 (1.00) PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1
R-Ketoprofen SCHEMBL195303 1.00 PTGS1 (1.00) PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1
Ketoprofen SCHEMBL8577572 1.00 PTGS1 (1.00) PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1
Dexketoprofen SCHEMBL29396875 1.00 PTGS1 (1.00) PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1
Ketoprofen SCHEMBL16757741 1.00 PTGS1 (1.00) PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1
Ketoprofen SCHEMBL679920 1.00 PTGS1 (1.00) PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1
R-Ketoprofen SCHEMBL29353694 1.00 PTGS1 (1.00) PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1
Ketoprofen SCHEMBL3843886 1.00 PTGS1 (1.00) PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1
Ketoprofen SCHEMBL8754790 1.00 PTGS1 (1.00) PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1
Ketoprofen SCHEMBL23391019 0.98 PTGS1 (0.97) PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 6177 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3841097-B1 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) 2026-05-20 EP claimed
EP-4255391-B1 LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION METRIOPHARM AG (CH) 2026-05-06 EP claimed
US-20260115161-A1 2-HYDROXY-OCTADECENE-9-CIS-OATE FOR USE IN THE TREATMENT OF ONCOLOGICAL PATHOLOGIES AND NEUROPATHIC PAIN LAMINAR PHARMACEUTICALS S A (ES) 2026-04-30 US claimed
US-12605432-B2 Combinations for antigen based therapy DIAMYD MEDICAL AB (SE) 2026-04-21 US claimed
US-12600696-B2 Aromatic compounds Xeniopro GmbH (DE) 2026-04-14 US claimed
US-20260069532-A1 METHOD FOR MORSELIZING AND/OR TARGETING PHARMACEUTICALLY ACTIVE PRINCIPLES TO SYNOVIAL TISSUE MEDINCELL S.A. (FR) 2026-03-12 US claimed
US-12558309-B2 Method for morselizing and/or targeting pharmaceutically active principles to synovial tissue MEDINCELL S.A. (FR) 2026-02-24 US claimed
US-12551433-B1 Associated forms of nonsteroidal anti-inflammatory drugs and local anesthetics INNOVATOR THERAPEUTICS, LLC (US) 2026-02-17 US claimed
US-20260000741-A1 METHOD OF AMELIORATING A PRO-INFLAMMATORY IMMUNOPHENOTYPE IN FARBER DISEASE SUBJECTS BY REPEATED ADMINISTRATION OF A RECOMBINANT HUMAN ACID CERAMIDASE ACERAGEN INC (US) 2026-01-01 US claimed
EP-4663187-A1 2-HYDROXY-OCTADECENE-9-CIS-OATE FOR USE IN THE TREATMENT OF ONCOLOGICAL PATHOLOGIES AND NEUROPATHIC PAIN Laminar Pharmaceuticals, S.A. (ES) 2025-12-17 EP claimed
EP-0693134-A1 ARYLALKANOIC ACID RESOLUTION MENARINI LAB (ES) 1996-01-24 EP claimed
EP-0668851-A1 A NOVEL ARYLPROPIONIC DERIVATIVE, A PROCESS FOR THE PREPARATION AND THE USE THEREOF AS AN ANALGESIC AGENT. MENARINI LAB (ES) 1995-08-30 EP claimed
WO-1994020449-A1 SALTS OF 2-(3-BENZOYLPHENYL)PROPIONIC ACID WITH ACHIRAL AND CHIRAL ORGANIC BASES AND PHARMACEUTICAL COMPOSITIONS THEREOF DOMPE'FARMACEUTICI SPA (IT) 1994-09-15 WO claimed
WO-1994020633-A1 ARYLALKANOIC ACID RESOLUTION LABORATORIOS MENARINI S.A. (ES) 1994-09-15 WO claimed
WO-1994011332-A1 A NOVEL ARYLPROPIONIC DERIVATIVE, A PROCESS FOR THE PREPARATION AND THE USE THEREOF AS AN ANALGESIC AGENT LABORATORIOS MENARINI S.A. (ES) 1994-05-26 WO claimed
EP-0419312-B1 METHOD FOR THE PRODUCTION OF OPTICALLY ACTIVE 2-ARYL-PROPIONIC ACIDS RHONE-POULENC SANTE (FR) 1993-08-04 EP claimed
EP-0330529-B1 PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE 2-ARYL-PROPIONIC ACIDS RHONE-POULENC SANTE (FR) 1993-03-31 EP claimed
US-5097064-A By reduction of arylacrylic acid using a rhodium derivative and water soluble chiral ligand as catalyst RHONE-POULENC SANTE (FR) 1992-03-17 US claimed
EP-0017169-A1 Improved anti-inflammatory combinations having reduced ulcerogenicity MERCK & CO. INC. (US) 1980-10-15 EP claimed
US-4097522-A Synthesis of m-benzoyl-hydratropic acid AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 1978-06-27 US claimed